Myeloma

Blood Cancers

Brain Cancer

Metastatic Breast Cancer

Breast Cancer

Childhood Cancers

Colorectal Cancer

Esophageal Cancer

Gastrointestinal stromal tumor

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancers

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Ovarian Cancer

Gynecologic Cancer

Head & Neck Cancer

Acute Myeloid Leukemia

Leukemia

Lung Cancer

Follicular Lymphoma

Mantle Cell Lymphoma

Non-Hodgkin Lymphoma

Lymphoma

Neuroendocrine Cancer

Rare Cancers

Sarcoma

Skin Cancer/Melanoma

Thyroid Cancer

News

Cancer Horizons

All News

Blogs

Caregiving

Diet and Exercise

Financial

Psychosocial

Recipes

Sexual Health

Side Effect

Survivorship

Videos

All Videos

CURE Connections

CURE Expert Connections®

CURE Speaking Out

CURE TV

Educated Patient Sound Bites

On Demand: Webinars

Conferences

Conference Coverage 

Conference Listing 

Events

CURE Adventures

CURE Awards

Educated Patient In Person Education

Educated Patient Virtual Education

Resources

Advocacy Groups

Art Gallery

Clinical Trial Corner

Heal®

Partners

Podcasts

Publications

Share Your Story

Subscribe

The myeloma condition center is a comprehensive resource for cancer news & oncologist insights on myeloma. Read more about cancer at CURE.

Myeloma | Oncology & Cancer News | CURE

CURE connects oncology patients, survivors, and caregivers with expert guidance, cancer updates, treatment education, and clinical trial access.

About Us

Advertise / Support

Editorial Board

Contact Us

CancerNetwork.com

TargetedOnc.com

OncLive.com

OncNursingNews.com

Terms & Conditions

Privacy

Do Not Sell My Information

CURE - Oncology & Cancer News for Patients & Caregivers

Facebook

Youtube

Instagram

Spotlight

Breast Cancer Webinar Series

Cancer Type

Bladder

Breast

Kidney

Lung

Ovarian

Prostate

Skin

About CURE

Press Releases

Write for CURE

1rem

Tumor

CURE’s myeloma page is a go-to resource for oncology news and updates in the world of myeloma Here, readers will find cancer articles, videos, podcasts, and more with expert insight into the latest treatments and research in myeloma.

Elie Fahed, MD, provides an overview of what multiple myeloma is, and Beth walks us through her frustrating journey to initial diagnosis as an atypical patient.

Multiple Myeloma Diagnosis: The Beginning of Beth’s Story

Cristina Gasparetto, MD, gives a brief overview of the multiple myeloma disease state and introduces us to Donna, one of her patients diagnosed with multiple myeloma.

Multiple Myeloma and Donna’s Symptoms: An Overview

Blood cancer treatments — and one treatment type, in particular — were the point of much discussion last week. The FDA said that it is investigating instances of secondary malignancies in patients with blood cancers treated with CAR-T cell therapy. Also, the drug manufacturer for a novel CAR-T cell therapy submitted an application to introduce the treatment into the United States market.

Blood cancers will continue to be a hot topic this week, as later in the week we’ll be covering the American Society of Hematology Annual Meeting. And before that, we’ll also be covering the San Antonio Breast Cancer Symposium.

Chance or CAR-T: Expert Weighs in on FDA Investigation

One of the biggest headlines in the cancer space last week was that the Food and Drug Administration (FDA) announced that they are investigating instances of T-cell malignancies — such as CAR-positive lymphoma — occurring in patients with blood cancers that were treated with CAR-T cell therapy.

CAR-T cell therapy is a newer type of blood cancer treatment that involves extracting patients’ blood and reengineering their immune T cells to find and fight cancer. Those new T cells are then multiplied and infused back into the patient. Since the first CAR-T cell product was approved in 2017, this treatment modality has drastically improved outcomes for patients with certain types of blood cancers.

It’s worth mentioning that the FDA’s Nov. 28 report about T-cell malignancies did not definitively say that CAR-T cell therapies are directly causing secondary diseases. They also did not mention the frequency at which these T-cell malignancies are occurring. I spoke with Dr. John Lister, who said that perhaps it’s the manufacturing process that could be the root cause, but perhaps it is also just chance, as research has shown that many patients with cancer hold a higher risk of developing a second cancer. For now, we’re just going to have to wait and see what further data tells us.

FDA Biologics License Application Filed for Obe-Cel for Adult R/R B-ALL

Also in CAR-T cell therapy news, last week a pharmaceutical company submitted a Biologics License Application to the FDA for their CAR-T cell therapy, obe-cel to be used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).

When a pharmaceutical company files a Biologics License Application to the FDA, they’re essentially asking the agency to allow them to bring the drug to the market. The company submitting the drug must provide the FDA with multiple pieces of information, including findings from preclinical and clinical studies showing that the drug is safe.

In this instance, the pharmaceutical company cited data from the FELIX study, from which, early data showed that 76% if patients responded to the therapy, including 54.3% who had a complete response, meaning that their disease essentially disappeared. Now, updated findings from the trial will be presented at the upcoming ASH Annual Meeting. 

For more news on cancer updates, research and education, don’t forget to 

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week. 

Top Headlines on CAR-T Cell Therapy

Ryan Johnson is a physician assistant in the emergency department who was working through the peak of the COVID-19 pandemic when he learned he had multiple myeloma. At the time, he questioned how he would remain safe and healthy, and if he’d be able to produce antibodies after receiving the vaccine.

Johnson answers these questions and more in this episode of the “Cancer Horizons” podcast, as he paints a vivid picture of what it was like to care for patients with COVID-19 while undergoing treatment for his cancer.

“I would like to get back to the old way of life and being able to go without a mask and being able to go to people's houses, you know, and just not have to worry about that stuff,” Johnson said in an interview with CURE®. “But it's the reality that the world isn't like that for me at this time.”

In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

As a devoted fashion lover from an early age, Donna McNutt has always been passionate about the art of dressing up to take on whatever the day may bring. And sometimes, the day brings a cancer diagnosis.

In this episode of the “Cancer Horizons” podcast, McNutt explains the genesis of her Instagram account, “Cancer Fashionista,” her love for fashion and how dressing for the day helps her get through the dark moments of cancer treatment.

“I dress for what the day is, what the night is and how I feel,” she said. “And I had to learn what that looked like with being in treatment. And, you know, sometimes I didn't really feel that good — I mean, not good at all. But I had to still go to an event or something. So it worked. It worked for me to get dressed.”

On this episode of the “Cancer Horizons” podcast, a woman with multiple myeloma shares how she made the best of her cancer treatment process by channeling her emotions through fashion expression.

‘Cancer Fashionista’ Discusses Finding Confidence During Cancer

A diagnosis of multiple myeloma can be daunting and overwhelming. But according to Dr. Andrew Yee, an assistant professor of medicine at Massachusetts General Hospital Cancer Center, it is also a very treatable disease.

 Talks Cancer” podcast, Yee went on to explain that the majority of patients do very well with treatment and continue to live the fullest lives possible.

“I do want to appreciate that, you know, getting this diagnosis is a really hard diagnosis, because you're moving forward with your life, and then your life gets turned upside down,” Yee said. “When I see a patient, usually the multiple myeloma is sort of front and center – it’s on the front burner. And the hope is that with treatment, the majority of patients I see, we can turn this from being a front burner (thing) to something that's on the back burner, or that's in the background.”

’s Educated Patient Multiple Myeloma Summit earlier this month, Dr. Yee sat down with 

 to discuss the signs and symptoms of the disease, what the current treatment paradigm looks like and offer some advice to newly diagnosed patients.

In this episode of the “CURE® Talks Cancer” podcast, we’re honoring Multiple Myeloma Awareness Month by speaking with Dr. Andrew Yee, about the signs and symptoms of this rare form of cancer, what the current treatment paradigm looks like and what advice he has for newly diagnosed patients.

The Basics of Multiple Myeloma

Each year, the Multiple Myeloma Research Foundation (MMRF) hosts its Laugh for Life event, which aims to educate, empower and inspire individuals to raise awareness and funds for multiple myeloma research.

Ahead of its event, CURE spoke with Tina Rettig, a caregiver for her husband who was diagnosed with multiple myeloma in 2010. Tina serves as a co-chair for the event, which will be held on May 6, to help to fund groundbreaking research initiatives like the MMRF’s most recent Direct to Patient Registry, a cornerstone of its 

“One of the big takeaways from (Laugh for Life) is the information that we put out there…(It raises) money, and money leads to research, and research leads to testing new treatments that can be approved,” Rettig said. “And there's no one treatment that fits everybody. So it's important that we have different levels of treatment, and that you can (live with) this disease.”

In addition, we spoke with Andrew Marcelle, and his father, Peter, who was diagnosed with multiple myeloma in 2016. Marcell will be receiving the “Spirit of Hope” award at this year’s event for his work in fundraising for the MMRF.

“It's such a big organization and there's so many people involved with it…(receiving this award) is very humbling and I'm excited for the event,” Marcelle said.

MMRF

In this episode of the “CURE Talks Cancer” podcast, we spoke with the co-chair of the MMRF’s Laugh for Life event, as well as this year’s “Spirit of Hope” award recipient.
 

Laugh for Life

Dr. Cesar Rodriguez has spent the last seven years dedicated to advancing the field of multiple myeloma — which he discussed in this week’s episode of the “

Rodriguez highlighted advances with precision medicine in the multiple myeloma treatment landscapes, and common questions patients have for their physicians.

Moreover, he also highlighted his recent trek to Patagonia with Moving Mountains for Multiple Myeloma, an effort partnered by 

 and the Multiple Myeloma Research Foundation. Through the trek, Rodriguez was able to meet with patients and their caregivers about a disease he has spent his career dedicated to finding more treatments for.

In this week’s episode of the “CURE Talks Cancer” podcast, we spoke with Dr. Cesar Rodriguez about precision medicine, and his recent trek to Patagonia with Moving Mountains for Multiple Myeloma.

Understanding Precision Medicine in Multiple Myeloma

It was one man’s passion for music that actually led to his 

In 2012, Ryan Anthony received his cancer diagnosis at just 43 years of age — something that was sparked by chronic aches and pains while playing his trumpet.

With this passion, he and fellow musicians created the Cancer Blows event, designed to raise both awareness and money to encourage 

Cancer Blows, an event by The Ryan Anthony Foundation, offers hope for many with cancer – all while raising awareness for multiple myeloma.

A Song for Hope

Ethan Hawes was a college student, studying abroad in Spain. Having returned home to the states after running the Madrid Marathon, Ethan thought he was experiencing lingering leg and hip pain from training, but in reality, it was actually something much different: a multiple myeloma diagnosis.

 Talks Cancer, we spoke with Ethan about his experience as a 22-year-old diagnosed with a rare cancer, and his advice for others going through a similar journey.

In this week’s episode of CURE Talks Cancer, we spoke with Ethan Hawes about his experience as a 22-year-old diagnosed with multiple myeloma, and his advice for others going through a similar journey.

Running the Marathon Called Cancer

Moving Mountains for Multiple Myeloma (MM4MM) is a collaboration to raise awareness and funds for myeloma research where patients, caregivers, doctors, nurses and loved ones take on challenging mountain climbs throughout the year. On this year’s domestic hike, a team of 20 explored the Havasu Falls region of the Grand Canyon.

In this week’s episode, we spoke with two climbers: Jamie Tinschert, who received a multiple myeloma diagnosis in June 2012, and Chris Seal, a marketing director for an oncology brand at Amgen — who also sponsored the Havasu Falls climb – about their experience and why the MM4MM treks are key to raising awareness for multiple myeloma.

We spoke with two members of the Moving Mountains for Multiple Myeloma team.

Moving Mountains

Former professional football player Elijah Alexander was enjoying life as a retired linebacker until his health took a turn for the worse in 2010. At first, his symptoms were written off as the result of years of wear and tear on his body from being an athlete, until one doctor finally ran more tests and diagnosed him with multiple myeloma. 

Elijah eventually passed away from the disease, but his wife, Kimberly, remains vocal about telling his story and spreading awareness about myeloma, which affects a higher proportion of African Americans than any other race. But still, many people are unfamiliar with the disease. 

Now, Kimberly is trying to change that, and encourages people to be more proactive about their health, not only during Minority Health Month, but throughout the year.

In this week's episode of CURE Talks Cancer, we spoke with Kimberly Alexander, who became an advocate for minority health after her husband was diagnosed with multiple myeloma.

Minorities and Myeloma: One Advocate's Story

Ashley Dieks and Dr. Saad Z. Usmani discussed how bicycling may help patients cope with the emotional and physical challenges of their myeloma diagnosis.

Patients and Caregivers Aim to Raise Funds for Myeloma Research  

SAR446523, an investigational antibody targeting GPRC5D, received FDA orphan drug status and is in phase 1 trials for relapsed/refractory multiple myeloma.

FDA Grants Orphan Drug Status to SAR446523 for Relapsed Myeloma

The FDA's Oncologic Drugs Advisory Committee has casted their votes on the utilization of certain treatments in the multiple myeloma patient population.

FDA Votes Against Proposed Blenrep Treatment Combo’s for Multiple Myeloma 

The FDA approved Lynozyfic for relapsed multiple myeloma, but serious risks require restricted use under a special safety program.

FDA Grants Accelerated Approval to Lynozyfic for Multiple Myeloma

Label updates have been approved by the FDA for the CAR T-cell therapies Breyanzi and Abecma in large B cell lymphoma and multiple myeloma, respectively.

FDA Approves CAR T Therapy Label Updates Across Various Blood Cancers

Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years.

Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’

For nearly 30 years, Dr. Jim Omel has had a front row seat to the changing landscape of multiple myeloma treatment.

Omel, 78, is a retired family practitioner from central Nebraska who first received a diagnosis of multiple myeloma in 1997, a cancer journey that began with a feeling of chronic pain in his lower back.

In the years since, Omel has undergone an evolving array with treatments, including radiation, autologous stem cell transplant, Revlimid (lenalidomide), Velcade (bortezomib) and dexamethasone, and faced recurrences of his disease in 2000, 2006 and 2010.

“In 1997 it was bleak,” Omel told CURE. “In 2025, the world is a totally different place for myeloma patients. We have a myriad of new treatments, effective treatments, and the vast majority of patients, 80%, can expect complete remission.”

An active patient advocate, Omel has lived without recurrence on multiple myeloma for 15 years. He sat down for an interview with CURE to discuss how life for patients with multiple myeloma has drastically changed in nearly 30 years.

How has life for patients with multiple myeloma changed since you received your diagnosis in 1997?

In 1997, it was bleak. In 2025, the world is a totally different place for myeloma patients. We have a myriad of new treatments, effective treatments, and the vast majority of patients, 80%, can expect complete remission, even [minimal residual disease]-negative status, and that just would have been unheard of in the year 2000. The year 2025, this year especially, has been a good one, and we have so many good immunotherapies now that we didn't have in the past, that I give new patients optimism. I use myself as an example. I'm an outlier when it comes to living that long, but new patients now can expect long, healthy lives. I use the analogy of diabetes. We cannot cure diabetes, but you can live with it, and we have good treatment for it. So I say that myeloma now is for the majority, not all, but for the majority of patients, it's a chronic disease. You can live with it, enjoy your life.

Transcript has been edited for clarity and conciseness.

Living with Multiple Myeloma: What a New Diagnosis Means for Your Future

Dr. Joshua Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 2025 ASCO Meeting. 

What Should Patients with Multiple Myeloma Know After ASCO 2025? 

Dr. Joshua K. Sabari and Dr. Nausheen Ahmed sat down to discuss topline takeaways in the realm of hematologic malignancies following the 

, highlighting what patients should know following the meeting.

"We had a great ASCO Meeting [with updates across] the myeloma and lymphoma fields. I am going to highlight some of the some of the studies that were presented that were [most] interesting," Ahmed began.

To kick things off, Ahmed highlighted the 

 which evaluated transplant-eligible patients with newly diagnosed multiple myeloma, and in the study, investigators evaluated treatment with subcutaneous Darzalex (daratumumab) plus Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone and Revlimid maintenance versus standard Velcade, Revlimid, and dexamethasone. The trial showed an improvement in stringent complete response and minimal residual disease (MRD) negativity with the investigate regimen compared with standard of care.

Ahmed continued by touching on the ADVANCE trial in the transplant-eligible, newly diagnosed myeloma patient population. The study evaluated treatment with Kyprolis (carfilzomib), Revlimid, and dexamethasone with or without Darzalex (daratumumab), finding that the investigative treatment showed a statistically significant improvement in minimal residual disease negativity, with no new safety signals.

She also touched on key takeaways in the lymphoma patient population, highlighting cellular therapies specifically. Ahmed highlighted the phase 1 study of KITE-363, an anti-CD19/CD20 CAR-T cell therapy for those with relapsed/refractory B -cell lymphoma. Investigators found that utilizing the therapeutic had a favorable safety and efficacy profile, and demonstrated a potential role as a next-generation CAR T product.

Myeloma

Latest News

Multiple Myeloma Diagnosis: The Beginning of Beth’s Story